Interim Report for the period July – September 2022

Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 · Lecanemab showed positive results in the pivotal Phase 3 study, Clarity AD, in early Alzheimer's disease, and both primary and all key secondary endpoints were met with high statistical significance · New lecanemab data were presented by Eisai at the Alzheimer's Association International Conference (AAIC), including data on a subcutaneous formulation of lecanemab · The FDA accepted the Biologics License Application (BLA) and granted priority review for